

Special Issue

Non-small Cell Lung Cancer with Targetable Driver Mutations

Message from the Guest Editors

Increased understanding of the molecular pathways in non-small cell cancer (NSCLC) has led to discoveries of a number of targetable oncogenic driver mutations. These discoveries have since led to the development of targeted therapies that have improved outcomes in certain subsets of patients with NSCLC. In this Special Issue, we will focus on the advancements in the diagnosis and treatment of NSCLC with targetable mutations. We invite original and review articles related to detection and treatment of NSCLC with driver mutations in the fields of molecular diagnostics, imaging, radiomics, artificial intelligence and machine learning, clinical trials, and treatment strategies.

Mr. Dexter P. Mendoza

Guest Editors

Dr. Subba Rao Digumarthy

Office of Thoracic Radiology, Massachusetts General Hospital, Founders 202, 55 Fruit St, Boston, MA 02114, USA

Mr. Dexter P. Mendoza

1. Massachusetts General Hospital, 55 Fruit St, Founders 202, Boston, MA 02114, USA
2. Harvard Medical School, Boston, MA 02114, USA

Deadline for manuscript submissions

closed (30 April 2021)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/49273

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)